Vicagrel is under clinical development by Jiangsu Vcare PharmaTech and currently in Pre-Registration for Acute Coronary Syndrome. According to GlobalData, Pre-Registration drugs for Acute Coronary Syndrome have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Vicagrel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vicagrel was under investigation for the treatment of the acute coronary syndrome, ischaemic stroke, and peripheral arterial disease. It was administered through the oral route as a capsule and suspension. It acts by targeting the ADP glucose receptor.
Jiangsu Vcare PharmaTech overview
Jiangsu Vcare PharmaTech is a Pharmaceuticals and Healthcare company that provides Medicine Manufacturing services. The company is Headquartered in Nanjing, Jiangsu, China.
For a complete picture of Vicagrel’s drug-specific PTSR and LoA scores, buy the report here.